



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
07/625,668	12/13/90	WALLACH	D WALLACH-4

ROGER L. BROWDY
BROWDY & NEIMARK
419 SEVENTH STREET, NW
WASHINGTON, DC 20004

EXAMINER	
BLIGAISKY, G	
ART UNIT	PAPER NUMBER
1814 S	
DATE MAILED:	

10/23/91

Please find below a communication from the EXAMINER in charge of this application.

Commissioner of Patents.

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a) (1) and (a) (2). However, this application fails to comply with one or more of the requirements of 37 CFR 1.821 through 1.825 for one or more of the reasons set forth on the attached form "Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures." Wherein attention is directed to paragraph (s) _____.


Elizabeth C Weimar
ELIZABETH C. WEIMAR
SUPERVISOR/PATENT EXAMINER
PT UNIT 24



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
07/625,668	12/13/90	WALLACH	D WALLACH-4

ROGER L. BROWDY
BROWDY & NEIMARK
419 SEVENTH STREET, NW
WASHINGTON, DC 20004



EXAMINER	
BUGAISKY, G	
ART UNIT	PAPER NUMBER
1814	
DATE MAILED:	

10/23/91

DOCKETED

11-23-91

Please find below a communication from the EXAMINER in charge of this application.

Commissioner of Patents.

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a) (1) and (a) (2). However, this application fails to comply with one or more of the requirements of 37 CFR 1.821 through 1.825 for one or more of the reasons set forth on the attached form "Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures." Wherein attention is directed to paragraph (s) _____.

Elizabeth C Weimar
ELIZABETH C. WEIMAR
SUPERVISORY PATENT EXAMINER
ART UNIT 184

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR § 1.821(a)(1) and (a)(2). However, this application fails to comply with one or more of the requirements of 37 CFR §§ 1.821 through 1.825 as follows:

1. This application clearly fails to comply with the collective requirements of §§ 1.821 through 1.825. Applicant's attention is directed to these regulations, a copy of which is attached.

2. This application does not conform exclusively to the requirements of §§ 1.821 through 1.825. The non-conforming material should be deleted. § 1.821(b).

3. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing," § 1.821(c).

4. This application does contain, as a separate part of the disclosure on paper copy, a "Sequence Listing." However, the "Sequence Listing" does not comply with the requirements of §§ 1.821 through 1.825 as follows:

a. The sequence data does not comply with the symbol and format requirements of paragraphs (b) through (p) of § 1.822. Specifically: _____

b. The "Sequence Listing" does not comply with the location and page requirements of paragraph (a) of § 1.823.

c. The "Sequence Listing" does not comply with the information requirements of paragraph (b) of § 1.823. Specifically: _____

d. Other: _____

5. The description and/or claims of the patent application mention a sequence that is set forth in the "Sequence Listing" but reference is not properly made to the sequence by use of a sequence identifier as required by § 1.821(d).

6. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by § 1.821(e).

7. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the computer readable form does not comply with the requirements of § 1.824. Specifically:

8. A statement that the content of the paper and computer readable copies are the same has not been submitted as required by § 1.821(f).

9. The amendment to or replacement of the paper and/or computer readable copies of the "Sequence Listing" does not comply with the requirements of § 1.825(a) through (c).

10. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable. Applicant must provide a substitute copy of the data in computer readable form accompanied by a statement that the substitute data is identical to that originally filed. § 1.825(d). Specifically: _____

11. Other: _____

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE ABOVE REQUIREMENTS. Failure to comply with the above requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR § 1.136. Direct the response to, and any questions about, this notice to the undersigned. A copy of this notice MUST be returned with your response.



For: Manager, Application Processing Division
(703) 308-1202 or 308-_____

Elizabeth C. Skinner
Examining Group 180
(703) 308-0254